logo
logo
HomeAbout UsPlatformInsights

Clinical Trial Insights

AllClinical TrialRegulatoryMerger & AcquisitionsBlogs
Hydronidone Shows Significant Fibrosis Regression in Phase 3 Trial for CHB-Associated Liver FibrosisClinical Trial Updates

23 May 2025

Hydronidone Shows Significant Fibrosis Regression in Phase 3 Trial for CHB-Associated Liver Fibrosis

Gyre Therapeutics announced positive Phase 3 results for Hydronidone (F351) in treating liver fibrosis associated with chronic hepatitis B (CHB) in Ch...

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination TherapyClinical Trial Updates

23 May 2025

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy

ImCheck Therapeutics announced positive interim data from its Phase I/II EVICTION study evaluating ICT01, a γ9δ2 T-cell activator, in combination with...

ImPact Biotech to Present ENLIGHTED Study Interim Analysis at ASCO 2025Clinical Trial Updates

23 May 2025

ImPact Biotech to Present ENLIGHTED Study Interim Analysis at ASCO 2025

ImPact Biotech announced that it will present interim data from its Phase 3 ENLIGHTED study of Padeliporfin VTP in patients with low-grade upper tract...

Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL AmyloidosisClinical Trial Updates

23 May 2025

Immix Biopharma's NXC-201 Shows Promising Results for Relapsed/Refractory AL Amyloidosis

Immix Biopharma announced positive results from its Phase 1/2 NEXICART-2 clinical trial of NXC-201, a sterically-optimized BCMA-targeted CAR-T cell th...

Kelun-Biotech Presents Positive Clinical Trial Data at ASCO 2025Clinical Trial Updates

23 May 2025

Kelun-Biotech Presents Positive Clinical Trial Data at ASCO 2025

Kelun-Biotech announced the publication of six abstracts from its clinical studies at the 2025 ASCO Annual Meeting. The abstracts highlight data on t...

Legend Biotech Presents New Data on CARVYKTI® and Pipeline Candidates at ASCO, EHA, and ASGCTClinical Trial Updates

23 May 2025

Legend Biotech Presents New Data on CARVYKTI® and Pipeline Candidates at ASCO, EHA, and ASGCT

Legend Biotech announced new data on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for multiple myeloma, to be presented at ASCO and EHA. Lo...

Lilly Announces ASCO 2025 Presentations on Oncology PipelineClinical Trial Updates

23 May 2025

Lilly Announces ASCO 2025 Presentations on Oncology Pipeline

Eli Lilly and Company announced that data from several investigational oncology therapies will be presented at the 2025 American Society of Clinical O...

Linvoseltamab Combination Therapy Shows Promising Results in Multiple MyelomaClinical Trial Updates

23 May 2025

Linvoseltamab Combination Therapy Shows Promising Results in Multiple Myeloma

Regeneron Pharmaceuticals announced positive initial results from the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with carfilzom...

Merus' Bispecific Antibody Shows Promising Results in Head and Neck CancerClinical Trial Updates

23 May 2025

Merus' Bispecific Antibody Shows Promising Results in Head and Neck Cancer

Merus announced positive Phase II data for its bispecific antibody petosemtamab in combination with Keytruda (pembrolizumab) for first-line treatment ...

MiraDx's MicroRNA-based Platform Predicts Cancer Treatment OutcomesClinical Trial Updates

23 May 2025

MiraDx's MicroRNA-based Platform Predicts Cancer Treatment Outcomes

MiraDx announced two studies to be presented at ASCO 2025, showcasing their mirSNP platform's ability to predict treatment-related toxicity and respon...

Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLCClinical Trial Updates

23 May 2025

Mythic Therapeutics Presents Positive Phase 1 Data for MYTX-011 in NSCLC

Mythic Therapeutics announced positive efficacy data from the Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate (ADC), in ...

Petosemtamab Plus Pembrolizumab Shows Strong Efficacy in Head and Neck CancerClinical Trial Updates

23 May 2025

Petosemtamab Plus Pembrolizumab Shows Strong Efficacy in Head and Neck Cancer

Merus N.V. announced positive interim data from a Phase 2 trial of petosemtamab in combination with pembrolizumab for first-line treatment of PD-L1+ r...

Pfizer to Present Phase 1 Data on MesoC2 ADC at ASCO 2025Clinical Trial Updates

23 May 2025

Pfizer to Present Phase 1 Data on MesoC2 ADC at ASCO 2025

Nona Biosciences announced that its collaborator, Pfizer, will present the Phase 1 clinical study design of MesoC2 (HBM9033/PF-08052666), a first-in-c...

Positive Phase II Results for CARsgen's Satri-cel in Advanced Gastric CancerClinical Trial Updates

23 May 2025

Positive Phase II Results for CARsgen's Satri-cel in Advanced Gastric Cancer

CARsgen Therapeutics announced positive results from a Phase II clinical trial (CT041-ST-01, NCT04581473) of satricabtagene autoleucel (satri-cel), a ...

Positive Updated Results for Avutometinib Plus Defactinib in Frontline Metastatic Pancreatic CancerClinical Trial Updates

23 May 2025

Positive Updated Results for Avutometinib Plus Defactinib in Frontline Metastatic Pancreatic Cancer

Verastem Oncology announced positive updated results from the RAMP 205 Phase 1/2 trial evaluating the combination of avutometinib and defactinib with ...

RWJBarnabas Health and Rutgers Cancer Institute to Present Cancer Research at ASCO 2025Clinical Trial Updates

23 May 2025

RWJBarnabas Health and Rutgers Cancer Institute to Present Cancer Research at ASCO 2025

RWJBarnabas Health and Rutgers Cancer Institute will present 45 abstracts and presentations at the 2025 ASCO Annual Meeting. Research highlights incl...

Rakuten Medical Announces Phase 3 Trial Progress for ASP-1929 Photoimmunotherapy at ASCO 2025Clinical Trial Updates

23 May 2025

Rakuten Medical Announces Phase 3 Trial Progress for ASP-1929 Photoimmunotherapy at ASCO 2025

Rakuten Medical announced that it will present a Trial in Progress poster at the 2025 ASCO Annual Meeting, showcasing its global Phase 3 clinical tria...

Servier to Present Updates on IDH-Mutated Cancer Research at ASCO 2025Clinical Trial Updates

23 May 2025

Servier to Present Updates on IDH-Mutated Cancer Research at ASCO 2025

Servier announced it will present updates from its research programs at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Presenta...

SystImmune to Present izalontamab brengitecan (iza-bren) Data at ASCO 2025Clinical Trial Updates

23 May 2025

SystImmune to Present izalontamab brengitecan (iza-bren) Data at ASCO 2025

SystImmune, Inc. announced that data from clinical trials evaluating izalontamab brengitecan (iza-bren), an EGFRxHER3 bispecific antibody-drug conjuga...

Taiho Oncology Presents Positive Data at ASCO 2025 Annual MeetingClinical Trial Updates

23 May 2025

Taiho Oncology Presents Positive Data at ASCO 2025 Annual Meeting

Taiho Oncology announced new data to be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Highlights include data on...

Tiziana Life Sciences Highlights Intranasal Foralumab for Moderate Alzheimer's DiseaseClinical Trial Updates

23 May 2025

Tiziana Life Sciences Highlights Intranasal Foralumab for Moderate Alzheimer's Disease

Tiziana Life Sciences announced positive advancements in moderate Alzheimer's disease treatment using intranasal foralumab, a fully human anti-CD3 mon...

Updated Elacestrant Data Highlights Combinability in Metastatic Breast CancerClinical Trial Updates

23 May 2025

Updated Elacestrant Data Highlights Combinability in Metastatic Breast Cancer

Menarini Group presented updated data from the Phase 1b/2 ELEVATE study at ASCO 2025, showcasing the efficacy and safety of elacestrant (ORSERDU®) in ...

Vergent Bioscience's Abenacianine Improves Lung Cancer Tumor Visualization in Phase 2B TrialClinical Trial Updates

23 May 2025

Vergent Bioscience's Abenacianine Improves Lung Cancer Tumor Visualization in Phase 2B Trial

Vergent Bioscience announced positive Phase 2B VISUALIZE trial results for abenacianine (VGT-309), a tumor-targeted fluorescent imaging agent. The tr...

Vistagen to Present Research on Itruvone and Fasedienol at ASCP ConferenceClinical Trial Updates

23 May 2025

Vistagen to Present Research on Itruvone and Fasedienol at ASCP Conference

Vistagen, a clinical-stage biopharmaceutical company, announced it will present at the 2025 American Society of Clinical Psychopharmacology (ASCP) Con...

XTANDI Shows Long-Term Overall Survival Benefit in Metastatic Hormone-Sensitive Prostate CancerClinical Trial Updates

23 May 2025

XTANDI Shows Long-Term Overall Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

Five-year follow-up data from the Phase 3 ARCHES trial (NCT02677896) demonstrates that XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) s...

Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AMLClinical Trial Updates

23 May 2025

Ziftomenib Shows Promise in Treating Relapsed/Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin announced positive pivotal data for ziftomenib, an oral menin inhibitor, in patients with relapsed/refractory (R/R) NPM1...

Avalyn Pharma Presents Positive Clinical Data for Inhaled Pulmonary Fibrosis Treatments at ATS 2025Clinical Trial Updates

21 May 2025

Avalyn Pharma Presents Positive Clinical Data for Inhaled Pulmonary Fibrosis Treatments at ATS 2025

Avalyn Pharma showcased positive clinical data for its lead programs, AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), at the American Thorac...

First-Ever Combined Implantation of MOTUS Device and TOPS™ System for Lumbar Spinal DegenerationClinical Trial Updates

21 May 2025

First-Ever Combined Implantation of MOTUS Device and TOPS™ System for Lumbar Spinal Degeneration

Drs. Lanman and Ament performed the first known combined implantation of the MOTUS total joint replacement device and the TOPS™ System at adjacent lum...

Improved Cardiac Surgery Outcomes with Active Chest Tube ClearanceClinical Trial Updates

21 May 2025

Improved Cardiac Surgery Outcomes with Active Chest Tube Clearance

ClearFlow, Inc. announced positive clinical trial results showing that its PleuraFlow Active Clearance Technology (ACT) System significantly improves ...

ONWARD Medical Achieves Fifth Successful Brain-Computer Interface ImplantClinical Trial Updates

21 May 2025

ONWARD Medical Achieves Fifth Successful Brain-Computer Interface Implant

ONWARD Medical announced the successful implantation of its investigational ARC-BCI® Therapy in two additional individuals with spinal cord injury, br...

Zymeworks Presents Preclinical Data for ZW1528, a Novel Bispecific Antibody for Respiratory InflammationClinical Trial Updates

20 May 2025

Zymeworks Presents Preclinical Data for ZW1528, a Novel Bispecific Antibody for Respiratory Inflammation

Zymeworks announced the presentation of preclinical data for ZW1528, a novel bispecific molecule targeting IL-4Rα and IL-33, at the American Thoracic ...

Be Biopharma Announces Preclinical Data for BE-102 in HypophosphatasiaClinical Trial Updates

19 May 2025

Be Biopharma Announces Preclinical Data for BE-102 in Hypophosphatasia

Be Biopharma presented preclinical data for BE-102, a B cell medicine, showing continuous secretion of active alkaline phosphatase (ALP) for up to six...

Cantargia's CAN10 Shows Promise in Inhibiting Vascular InflammationClinical Trial Updates

19 May 2025

Cantargia's CAN10 Shows Promise in Inhibiting Vascular Inflammation

Cantargia AB announced promising preclinical results for CAN10, an antibody targeting IL1RAP, in vascular inflammation models. The study, published i...

CureGene's CG-0416 Shows Promise as Dual-Action Therapy for Obesity and MASHClinical Trial Updates

19 May 2025

CureGene's CG-0416 Shows Promise as Dual-Action Therapy for Obesity and MASH

CureGene Pharmaceuticals announced preclinical data for its investigational drug, CG-0416, a liver-targeted thyroid hormone receptor beta (THR-β) prod...

IMVARIA Presents Multi-Site Clinical Data on AI Diagnostic Service for Idiopathic Pulmonary Fibrosis at ATS 2025Clinical Trial Updates

19 May 2025

IMVARIA Presents Multi-Site Clinical Data on AI Diagnostic Service for Idiopathic Pulmonary Fibrosis at ATS 2025

IMVARIA Inc. announced the presentation of multi-site clinical experience results with its FDA-authorized AI diagnostic service, Fibresolve, at the AT...

Innate Pharma's Abstracts Selected for ASCO 2025 Annual MeetingClinical Trial Updates

19 May 2025

Innate Pharma's Abstracts Selected for ASCO 2025 Annual Meeting

Innate Pharma announced that four abstracts featuring its clinical-stage drugs will be presented at the American Society of Clinical Oncology (ASCO) 2...

LIfT BioSciences Presents Preclinical Data on Immunomodulatory Alpha Neutrophils (IMANs) for Solid TumorsClinical Trial Updates

19 May 2025

LIfT BioSciences Presents Preclinical Data on Immunomodulatory Alpha Neutrophils (IMANs) for Solid Tumors

LIfT BioSciences announced the presentation of preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) at the ISCT 2025 Annu...

Positive Phase 1b Results for TX45 in Group 2 Pulmonary HypertensionClinical Trial Updates

19 May 2025

Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension

Tectonic Therapeutic announced positive complete results from Part A of its Phase 1b clinical trial of TX45 in patients with Group 2 Pulmonary Hyperte...

Abbott's FreeStyle Libre CGM Reduces Cardiovascular Hospitalizations in People with DiabetesClinical Trial Updates

16 May 2025

Abbott's FreeStyle Libre CGM Reduces Cardiovascular Hospitalizations in People with Diabetes

New data from Abbott's REFLECT real-world studies show that using FreeStyle Libre continuous glucose monitoring (CGM) technology is associated with a ...

Novartis Presents Promising Oncology and Hematology Data at ASCO and EHAClinical Trial Updates

16 May 2025

Novartis Presents Promising Oncology and Hematology Data at ASCO and EHA

Novartis announced the presentation of data from 60 abstracts at the 2025 ASCO Annual Meeting and EHA 2025 Congress. The data showcases the momentum ...

← PrevPage 9 of 10Next →